Download Citation on ResearchGate | Advances in the diagnosis, pathogenesis and treatment of CIDP | Chronic inflammatory demyelinating. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens. CIDP is an acquired immune-mediated inflammatory disorder sometimes Advances in the diagnosis, pathogenesis and treatment of CIDP.
|Published (Last):||17 August 2007|
|PDF File Size:||10.55 Mb|
|ePub File Size:||2.78 Mb|
|Price:||Free* [*Free Regsitration Required]|
Advances in the diagnosis, pathogenesis and treatment of CIDP
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Search for additional papers on this topic. Current diagnosis of CIDP: Brannagan Journal of the peripheral nervous system: This paper has been referenced on Twitter 1 time over the past 90 days.
Antonis FanouriakisDimitrios T. Advances in our understanding of the underlying immunopathology in CIDP have identified new targets for future therapeutic efforts, including T cells, B cells, and transmigration and transduction molecules.
Advances in the diagnosis, pathogenesis and treatment of CIDP.
Showing of 60 extracted citations. This Pathogenesiss highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens, and discusses current treatments, ongoing challenges and future therapeutic directions. Pathogenesis and treatment of CNS lupus. MRI assessment including apparent diffusion coefficient. Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies.
References Publications referenced by this paper. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Armati Journal of the peripheral nervous system: Showing of references.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Immunoglobulins, Intravenous Demyelinating peripheral neuropathy Polyneuropathy. Dalakas The Lancet Neurology John David PollardPatricia J.
An open label clinical trial of complement inhibition in multifocal motor neuropathy. Commonly used immunosuppressive drugs offer minimal benefit, necessitating the development of new therapies for treatment-refractory patients.
Despite clinical challenges in diagnosis-owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination-consensus criteria advanecs to have been reached for research or clinical practice.
Evidence from Human and Animal Studies: New biomarkers treamtent scoring systems represent emerging tools with the potential to predict therapeutic responses and identify patients with active disease for enrollment into clinical trials.
Kenneth Craig Gorson Therapeutic advances in neurological disorders Chronic inflammatory demyelinating polyneuropathy CIDP is the most common chronic autoimmune neuropathy.
Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy. BoumpasGeorge K. Despite clinical challenges in diagnosis—owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination—consensus criteria seem to have pathoegnesis reached for research or clinical practice.
Bertsias Current opinion in rheumatology An update on the management of chronic inflammatory demyelinating polyneuropathy.
Citations Publications citing this paper. Topics Discussed in This Paper. Maintenance therapy with IVIg can induce sustained remission, increase quality of life and prevent further axonal loss, but caution is needed to avoid overtreatment. Skip to search form Skip to main content.
From This Paper Figures, tables, and topics from this paper. Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy Marinos C.